Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention
Clinical Pharmacology & Therapeutics · 2026-08 · 120 (2) · 531-541
DOI: 10.1002/cpt.70338 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 15.05.2026. Verfasst von Danwei Shao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, Nor…. Hauptthemen laut MEDLINE: Clopidogrel, Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP3A. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHGRI NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/rapid/ultrarapid metabolizers: NM/RM/UMs). However, the impact of CYP2C19 or CYP3A4 inhibitor use on clopidogrel clinical effectiveness remains unclear. Rates of major atherothrombotic events (MAE) over 12 months after percutaneous coronary intervention (PCI) were evaluated in 3,242 patients across three sites who underwent CYP2C19 genotype testing and received P2Y 12 inhibitor therapy. Overall, 6.8% of patients were co‐prescribed a moderate or strong inhibitor of either CYP2C19 or CYP3A4, as defined by the U.S. Food and Drug Administration. In CYP2C19 genotype‐predicted NM/RM/UMs treated with clopidogrel ( n = 1,624), the MAE rates were numerically higher, but not significantly different in patients receiving either a CYP2C19 or a CYP3A4 inhibitor vs. no inhibitor (18.4 vs. 12.8 events/100 patient‐years, adjusted hazard ratio (HR) 1.51, 95% confidence interval (CI), 0.85–2.68, P = 0.155). When evaluating CYP2C19 inhibitor and CYP3A4 inhibitor use separately, MAE rates were higher in clopidogrel‐treated NM/RM/UMs receiving a CYP2C19 inhibitor compared to no inhibitor (adjusted HR 2.22, 95% CI 1.01–4.91, P = 0.048), but no significant difference was observed in those receiving a CYP3A4 inhibitor compared to no inhibitor (adjusted HR 1.26, 95% CI 0.57–2.75, P = 0.569). These results suggest that concomitant use of a CYP2C19 inhibitor, but not a CYP3A4 inhibitor, may contribute to phenoconversion and decreased clopidogrel clinical effectiveness after PCI in CYP2C19 genotype‐predicted NM/RM/UMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Division of Cardiology and McAllister Heart Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Division of Cardiology, Department of Medicine, College of Medicine-Jacksonville, University of Florida, Jacksonville, Florida, USA.
- Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Danwei Shao, Jean G Malavé, Francesco Franchi, Ellen C Keeley, Dominick J Angiolillo, Larisa H Cavallari, Craig R Lee
Förderung
- NHGRI NIH HHS
- NCATS NIH HHS
- NHLBI NIH HHS
- National Institutes of Health (NIH) National Heart, Lung, and Blood Institute
- NIGMS NIH HHS
- National Human Genome Research Institute
- National Center for Advancing Translational Sciences
- National Institute of General Medical Sciences
Zitieren
APA
Shao, D., Malavé, J. G., Rossi, J. S., Franchi, F., Keeley, E. C., Angiolillo, D. J., Stouffer, G. A., Cavallari, L. H., & Lee, C. R. (2026). Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention. Clinical Pharmacology & Therapeutics, 120(2), 531-541. https://doi.org/10.1002/cpt.70338
Vancouver
Shao D, Malavé JG, Rossi JS, Franchi F, Keeley EC, Angiolillo DJ, et al. Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention. Clinical Pharmacology & Therapeutics. 2026;120(2):531-541. doi:10.1002/cpt.70338
BibTeX
@article{Shao2026,
author = {Shao, Danwei and Malavé, Jean G and Rossi, Joseph S and Franchi, Francesco and Keeley, Ellen C and Angiolillo, Dominick J and Stouffer, George A and Cavallari, Larisa H and Lee, Craig R},
title = {Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {120},
number = {2},
pages = {531--541},
doi = {10.1002/cpt.70338}
}
EUVIMED